Uppsala, Sweden, Oct. 21, 2016 (GLOBE NEWSWIRE) -- The pharmaceutical company Oasmia Pharmaceutical AB (NASDAQ:OASM) announce
today that the company is in discussions concerning acquisition of a novel cancer project.
More information will be released on Monday at the latest.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary
oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery
systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and
NASDAQ Stockholm (OASM.ST).
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com
